Rosuvastatin calcium
Pro Research Analysisby 
Searched over 200M research papers for "rosuvastatin calcium"
Advances in Rosuvastatin Calcium Formulations: Enhancing Bioavailability and Therapeutic Efficacy
Introduction to Rosuvastatin Calcium
Rosuvastatin calcium is a widely used statin for lowering cholesterol and managing hyperlipidemia. Despite its efficacy, it suffers from poor oral bioavailability, typically not exceeding 20%, due to its low solubility and extensive first-pass metabolism . Recent research has focused on developing advanced drug delivery systems to overcome these limitations and improve its pharmacokinetic and pharmacodynamic profiles.
Self Nanoemulsifying Drug Delivery System (SNEDDS)
Enhanced Solubility and Bioavailability
The self nanoemulsifying drug delivery system (SNEDDS) has shown promise in enhancing the solubility and bioavailability of rosuvastatin calcium. By utilizing a combination of oils, surfactants, and co-surfactants, researchers have optimized formulations that significantly improve drug dissolution and stability. The optimized SNEDDS formulation demonstrated a 2.45-fold increase in bioavailability compared to the drug in suspension.
Formulation and Evaluation
The SNEDDS formulations were evaluated for various parameters, including self-emulsifying time, robustness to dilution, droplet size, and zeta potential. The optimized system exhibited a droplet size of less than 200 nm and a zeta potential of -29.5 ± 0.63, indicating good stability and potential for enhanced absorption.
Solid Lipid Nanoparticles (SLNs)
Targeted Drug Delivery
Solid lipid nanoparticles (SLNs) have been developed to target low-density lipoprotein receptors, enhancing the therapeutic efficacy of rosuvastatin calcium. Surface-engineered SLNs using ligands like Phospholipon 90G and DSPE-mPEG-2000 have shown improved biopharmaceutical performance, making them a novel approach for managing hyperlipidemia.
Improved Pharmacokinetics and Pharmacodynamics
SLNs have demonstrated significant improvements in the pharmacokinetic and pharmacodynamic profiles of rosuvastatin calcium. Studies have shown that SLNs can enhance the drug's bioavailability by up to 4.6-fold and provide sustained drug release, leading to better therapeutic outcomes in hyperlipidemic models .
PEGylated Chitosan Nanoparticles
Long-Circulating Nanoparticles
PEGylated chitosan nanoparticles have been formulated to extend the circulation time of rosuvastatin calcium, thereby improving its pharmacokinetic profile. These nanoparticles showed prolonged drug release over 72 hours and enhanced lipid-lowering effects in hyperlipidemic rat models compared to plain rosuvastatin.
Sustained Release and Stability
The PEGylated chitosan nanoparticles were optimized for particle size, zeta potential, and drug entrapment efficiency. In vitro studies revealed a sustained drug release profile, making these nanoparticles a potential modality for long-term management of hyperlipidemia.
Immediate Release Tablets with Tribasic Calcium Phosphate
Stabilization and Rapid Dissolution
Immediate release tablets of rosuvastatin calcium stabilized with tribasic calcium phosphate have been developed to address the drug's instability during storage. These tablets exhibited rapid disintegration and dissolution, with 85% of the drug released within 15 minutes, and maintained chemical stability under stress conditions.
Conclusion
Recent advancements in the formulation of rosuvastatin calcium, including SNEDDS, SLNs, PEGylated chitosan nanoparticles, and stabilized immediate release tablets, have significantly improved its bioavailability and therapeutic efficacy. These innovative drug delivery systems offer promising solutions for enhancing the clinical outcomes of rosuvastatin calcium in the management of hyperlipidemia and related cardiovascular conditions.
Sources and full results
Most relevant research papers on this topic